Linked Life Data

11735111

Source:http://linkedlifedata.com/resource/pubmed/id/11735111

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Suppl 12
pubmed:dateCreated
2001-12-5
pubmed:abstractText
Recombinant factor VIIa (rFVIIa; NovoSeven), Novo Nordisk, Bagsvaerd, Denmark) has been used to treat more than 6,500 patients with hemophilia or other bleeding disorders, and by May 2001, more than 180,000 standard doses had been administered. Clinical experience to date suggests that rFVIIa is safe and effective, with a very low incidence of thrombotic events being reported. Moreover, in the majority of cases, thrombotic events appear to be caused by improvements in the hemostatic system, rather than a direct effect of the agent itself.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0037-1963
pubmed:author
pubmed:copyrightInfo
Copyright 2001 by W.B. Saunders Company.
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
48-50
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Recombinant factor VIIa (Novoseven) and the safety of treatment.
pubmed:affiliation
University of North Carolina, Chapel Hill, NC, USA.
pubmed:publicationType
Journal Article, Review